EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma

Juliette Penichoux, Pierre Decazes, Cédric Rossi, Pierre Sesques iD, Corinne Haioun, Eric Durot iD, Nicolas Gower, Alexandre Willaume iD, Lucie Oberic iD, Jérome Paillassa, Chloé Antier, Loic Renaud iD und 18 weitere

Hematological Oncology · 2025

DOI: 10.1002/hon.70117 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hematological Oncology, 2025. Verfasst von Juliette Penichoux und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and INSERM U1245, Center Henri Becquerel, Rouen, France. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse, Mediastinal Neoplasms, Body Composition. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary mediastinal large B‐cell lymphoma (PMBL) is a rare entity that predominantly affects young female patients and typically presents as a large and compressive anterior mediastinal mass. Accumulating evidence suggests relationships among PMBL patient body composition (BC), cancer outcomes, and treatment‐related toxicities. The aim of this study was to evaluate the impact of BC on PMBL patients using PET‐CT images acquired pretreatment. Two hundred nineteen patients were included in an ancillary analysis of a multicenter retrospective LYSA cohort of treatment‐naïve adult PMBL patients who received first‐line treatment with ACVBP, CHOP14 or CHOP21 plus anti‐CD20. Anthropometric parameters were assessed from the baseline PET‐CT image using two methods: (i) manual segmentation at the L3 level and (ii) automatic software‐based multislice measurements with Anthropometer3DNet. The median age was 35.4 years (range 18–88 years), and the median body mass index was 23.8 kg/m 2 (15.6; 40.8). Overall, 137 patients were treated with R‐ACVBP, 44 received R‐CHOP14, and 38 were treated with R‐CHOP21. Patients with low lean body mass had a higher incidence of febrile neutropenia, both in the overall cohort (25% vs. 12.6%, p = 0.02) and in the R‐ACVBP subgroup (35.7% vs. 19.4%, p = 0.03). Univariate analysis showed that in patients treated with R‐ACVBP, subcutaneous low adiposity, determined by 3D measurements, was associated with overall survival (OS) ( p = 0.04). At 3 years, the OS (95% CI) was 96% (93–100) in above‐median adiposity patients and 86% (78–95) in below‐median adiposity patients. Low lean body mass (LBM), assessed from the pretreatment PET‐CT images using automatic Anthropometer3DNet software, may serve as a predictive marker for acute treatment‐related toxicity in PMBL patients, particularly those receiving the dose‐intensive R‐ACVBP regimen. Additionally, depletion of the subcutaneous fat mass was correlated with an increased risk of mortality, highlighting the importance of a comprehensive BC assessment in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseMediastinal NeoplasmsBody CompositionHumansFemaleMiddle AgedAdultMaleAgedAdolescentRetrospective StudiesYoung AdultAged, 80 and overCyclophosphamideDoxorubicinVincristinePrednisoneRituximabTreatment OutcomePositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

body compositiondose‐intensive treatmentfebrile neutropeniaoutcomesprimary mediastinal large B‐cell lymphoma

Substanzen

CyclophosphamideDoxorubicinVincristinePrednisoneRituximab

Autor:innen und Institutionen

  • Department of Hematology and INSERM U1245, Center Henri Becquerel, Rouen, France.
  • Department of Nuclear Medicine and AIMS, Center Henri Becquerel, Rouen, France.
  • Université Bourgogne Europe, CHU Dijon Bourgogne, Hématologie, INSERM1231 CTM Equipe Epi2THM, Dijon, France.
  • Department of Hematology, Hospices Civils de Lyon, Pierre-Bénite, France.
  • Lymphoid Malignancies Unit, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Créteil, France.
  • Department of Hematology, CHU de Reims, Reims, France.

ORCID-Profile: Pierre Sesques, Eric Durot, Alexandre Willaume, Lucie Oberic, Loic Renaud, Kamel Laribi, Vincent Camus

Zitieren

APA

Penichoux, J., Decazes, P., Rossi, C., Sesques, P., Haioun, C., Durot, E., Gower, N., Willaume, A., Oberic, L., Paillassa, J., Antier, C., Renaud, L., Tournilhac, O., Thieblemont, C., Besson, C., Lebras, L., Choquet, S., Le Du, K., Bonnet, C., …, & Camus, V. (2025). Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70117

Vancouver

Penichoux J, Decazes P, Rossi C, Sesques P, Haioun C, Durot E, et al. Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma. Hematological Oncology. 2025. doi:10.1002/hon.70117

BibTeX
@article{Penichoux2025,
  author = {Penichoux, Juliette and Decazes, Pierre and Rossi, Cédric and Sesques, Pierre and Haioun, Corinne and Durot, Eric and Gower, Nicolas and Willaume, Alexandre and Oberic, Lucie and Paillassa, Jérome and Antier, Chloé and Renaud, Loic and Tournilhac, Olivier and Thieblemont, Catherine and Besson, Caroline and Lebras, Laure and Choquet, Sylvain and Le Du, Katell and Bonnet, Christophe and Bailly, Sarah and Damaj, Ghandi and Laribi, Kamel and Houot, Roch and Chauchet, Adrien and Becker, Stéphanie and Tonnelet, David and Tilly, Hervé and Jardin, Fabrice and Lévêque, Emilie and Camus, Vincent},
  title = {Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70117}
}
Kostenlos starten →